Edition:
United States

Ocera Therapeutics Inc (OCRX.OQ)

OCRX.OQ on NASDAQ Stock Exchange Capital Market

1.79USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,373
52-wk High
$2.95
52-wk Low
$0.54

Chart for

About

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine... (more)

Overall

Beta: 2.40
Market Cap(Mil.): $47.46
Shares Outstanding(Mil.): 26.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy

* Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy in development for treatment of hepatic encephalopathy

Nov 02 2017

BRIEF-Ocera Therapeutics Q2 loss per share $0.23

* Ocera Therapeutics reports second quarter 2017 financial results

Aug 01 2017

Competitors

Earnings vs. Estimates